exRNAdisease

Entry Detail

---



General Information

Database ID: exR0275388 RNA Name: hsa-miR-18a-5p RNA Type: miRNA Chromosome: chr13 Starnd: + Coordinate: Start Site(bp): 91350756 End Site(bp): 91350778 External Links: hsa-miR-18a-5p

Disease Information

Disease Name: Advanced Adenoma Disease Category: Cancers MeSH ID: D000236 Type: Neoplasms/Neoplasms, Glandular and Epithelial Alias: Adenoma//Adenomas//Adenoma, Follicular//Adenomas, Follicular//Follicular Adenoma//Follicular Adenomas//Adenoma, Trabecular//Adenomas, Trabecular//Trabecular Adenoma//Trabecular Adenomas//Adenoma, Monomorphic//Adenomas, Monomorphic//Monomorphic Adenoma//Monomorphic Adenomas//Adenoma, Papillary//Adenomas, Papillary//Papillary Adenoma//Papillary Adenomas//Adenoma, Basal Cell//Adenomas, Basal Cell//Basal Cell Adenoma//Basal Cell Adenomas//Adenoma, Microcystic//Adenomas, Microcystic//Microcystic Adenoma//Microcystic Adenomas

Expression Detail

GEO ID: GSE25609 Description: Plasma microRNA profiling by microarray elucidates several candidate biomarkers for colorectal cancer screening Experimental Design: Cancer vs Control Case Disease Type: Advanced Adenoma Case Disease SubType: NA Case Sample: Advanced Adenoma Post surgery Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand PATZ1 chr22 31325804 31346346 - TUBA4A chr2 219249710 219278170 - SURF4 chr9 133361450 133376166 - DDX5 chr17 64498254 64508199 - SND1 chr7 127652194 128092609 + HIF1AN chr10 100529072 100559998 + SIK2 chr11 111602449 111730855 + FKBP1A chr20 1368978 1393172 - USP10 chr16 84699978 84779922 + PARL chr3 183829271 183884933 - ASF1B chr19 14119512 14136613 - PRPF38B chr1 108692310 108702928 + ADAT2 chr6 143422832 143450695 - ZNF12 chr7 6688433 6706947 - DNAJC9 chr10 73183362 73247255 - AC131160.1 chr3 183815568 183884889 - ACSS2 chr20 34872146 34927962 + MRPS18A chr6 43671303 43687791 - XRCC6 chr22 41621119 41664048 + ROMO1 chr20 35699272 35700984 + PEX5 chr12 7188685 7218574 + NDUFV2 chr18 9102630 9134345 + UBE2Z chr17 48908407 48929056 + NOP58 chr2 202265736 202303661 + RNF4 chr4 2462220 2625320 + CHD1 chr5 98853985 98928957 - ATP2B1 chr12 89588049 89709300 - SLC41A1 chr1 205789094 205813748 - NCDN chr1 35557473 35567274 + HMGCS1 chr5 43287470 43313512 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000712 chr16 68208276 68225678 + hsa_circ_0001186 chr21 35475133 35475818 + hsa_circ_0001247 chr22 46125304 46136418 + hsa_circ_0000921 chr19 30476129 30477324 + hsa_circ_0000943 chr19 47421744 47440665 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC073896.4 chr12 56162359 56190284 - AC093010.3 chr3 114314501 114329714 - AC145207.5 chr17 81878425 81881106 - AL162171.3 chr14 88589231 88592408 + AP005263.1 chr18 9102736 9254346 + CASC2 chr10 118046279 118210158 + GAS5 chr1 173858559 173868882 - NEAT1 chr11 65422774 65445540 + SNHG1 chr11 62851984 62855953 - SNHG15 chr7 44983023 44986961 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE25609 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 826 Sample treatment protocol: Briefly, samples were centrifuged at 1,600×g for 10 min at 4 ºC to spin down blood cells, and plasma was transferred into new tubes, followed by further centrifugation at 16,000×g for 10 minutes at 4ºC to completely remove cellular components. RNA Extract protocol: NA RNA library preparation protocol: Biotinylated cDNA were prepared with the Illumina® TotalPrep™ RNA Amplification Kit (Ambion).

Reference

PMID: 23267864 Title: Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study Author: Gir¨¢ldez MD, Lozano JJ, Ram¨ªrez G, Hijona E, Bujanda L, Castells A, Gironella M Journal: Clin Gastroenterol Hepatol. 2013 Jun;11(6):681-8.e3. Description: We investigated whether plasma levels of miRNA can differentiate patients with CRC from healthy individuals. We also investigated whether plasma samples from patients with premalignant neoplastic lesions, such as advanced adenomas (AAs), also had a different expression pattern of miRNAs.